Phase 3 Study to Evaluate the Long-Term Safety and Tolerability of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain

Trial Profile

Phase 3 Study to Evaluate the Long-Term Safety and Tolerability of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs Bevenopran (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Registrational
  • Acronyms ASCENT
  • Sponsors Cubist Pharmaceuticals
  • Most Recent Events

    • 23 Oct 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Jul 2013 The phase III programme of bevenopran for opioid induced constipation is called ASCENT, according to a media release from Cubist Pharmaceuticals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top